An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and a Comparison to Subcutaneous (SC) Injection in Human Immunodeficiency Virus (HIV) Subjects Diagnosed With Kaposi Sarcoma (KS)
Sponsor: National Cancer Institute (NCI)
This PHASE1 trial investigates HIV Infections and Kaposi Sarcoma and is currently completed. National Cancer Institute (NCI) leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Apr 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Apr 2019 — Apr 2020 [monthly]
Recruiting PHASE1
-
Sep 2018 — Apr 2019 [monthly]
Recruiting PHASE1
Phase: EARLY_PHASE1 → PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Recruiting EARLY_PHASE1
-
Dec 2017 — Jun 2018 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2017 — Dec 2017 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Jun 2017 — Aug 2017 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
- Navidea Biopharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .